Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors

New and emerging HDAC inhibitors for cancer treatment

(2014) Alison C. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Predicting the structures of complexes between phosphoinositide 3-kinase (PI3K) and romidepsin-related compounds for the drug design of PI3K/histone deacetylase dual inhibitors using computational docking and the ligand-based drug design approach

(2014) Akifumi Oda et al.   JOURNAL OF MOLECULAR GRAPHICS & MODELLING

Epigenetics and Oncology

(2014) Padmaja Mummaneni et al.   PHARMACOTHERAPY

MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor

(2013) A. R. Chakraborty et al.   BLOOD

EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition

(2013) T. Nakagawa et al.   CANCER RESEARCH

Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS

(2013) Takashi Yoshioka et al.   GYNECOLOGIC ONCOLOGY

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics

(2013) Akintunde Akinleye et al.   Journal of Hematology & Oncology

Targeting PI3K in Cancer: Any Good News?

(2013) Miriam Martini et al.   Frontiers in Oncology

Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors

(2012) Ken Saijo et al.   CANCER SCIENCE

Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling

(2012) C. Qian et al.   CLINICAL CANCER RESEARCH

Activity-based kinase profiling of approved tyrosine kinase inhibitors

(2012) Daisuke Kitagawa et al.   GENES TO CELLS

Romidepsin: a novel histone deacetylase inhibitor for cancer

(2011) Erin M Bertino et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Structural Basis for Activation and Inhibition of Class I Phosphoinositide 3-Kinases

(2011) Oscar Vadas et al.   Science Signaling

CAL-101, a p110  selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

(2010) B. J. Lannutti et al.   BLOOD

Total Synthesis of the Bicyclic Depsipeptide HDAC Inhibitors Spiruchostatins A and B, 5′′-epi-Spiruchostatin B, FK228 (FR901228) and Preliminary Evaluation of Their Biological Activity

(2009) Koichi Narita et al.   CHEMISTRY-A EUROPEAN JOURNAL

PI 3-kinase and cancer: changing accents

(2009) Peter K Vogt et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of Drug-Resistant and Drug-Sensitizing Mutations in the Oncogenic PI3K Isoform p110α

(2008) Eli R. Zunder et al.   CANCER CELL

The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†

(2008) Adrian J. Folkes et al.   JOURNAL OF MEDICINAL CHEMISTRY